A detailed history of High Tower Advisors, LLC transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 306 shares of CAPR stock, worth $5,657. This represents 0.0% of its overall portfolio holdings.

Number of Shares
306
Previous 6,301 95.14%
Holding current value
$5,657
Previous $30,000 86.67%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.56 - $15.21 $21,342 - $91,183
-5,995 Reduced 95.14%
306 $4,000
Q2 2024

Aug 13, 2024

BUY
$4.63 - $7.09 $25,002 - $38,286
5,400 Added 599.33%
6,301 $30,000
Q1 2024

May 06, 2024

BUY
$3.61 - $6.88 $3,252 - $6,198
901 New
901 $6,000
Q4 2022

Feb 08, 2023

BUY
$3.36 - $6.55 $10,083 - $19,656
3,001 Added 17.77%
19,885 $76,000
Q3 2022

Nov 09, 2022

SELL
$3.61 - $6.08 $12,992 - $21,881
-3,599 Reduced 17.57%
16,884 $102,000
Q2 2022

Aug 10, 2022

SELL
$2.89 - $4.51 $4,046 - $6,314
-1,400 Reduced 6.4%
20,483 $72,000
Q1 2022

May 12, 2022

BUY
$2.83 - $5.68 $61,928 - $124,295
21,883 New
21,883 $75,000
Q4 2021

Feb 10, 2022

SELL
$2.89 - $4.16 $155,944 - $224,473
-53,960 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$3.8 - $5.23 $181,108 - $249,261
47,660 Added 756.51%
53,960 $215,000
Q2 2021

Aug 06, 2021

SELL
$3.16 - $5.72 $18,960 - $34,320
-6,000 Reduced 48.78%
6,300 $33,000
Q1 2021

May 10, 2021

SELL
$3.63 - $7.93 $14,520 - $31,720
-4,000 Reduced 24.54%
12,300 $57,000
Q4 2020

Feb 10, 2021

BUY
$3.43 - $5.23 $20,580 - $31,380
6,000 Added 58.25%
16,300 $56,000
Q3 2020

Nov 13, 2020

SELL
$4.08 - $9.81 $11,016 - $26,487
-2,700 Reduced 20.77%
10,300 $55,000
Q2 2020

Aug 10, 2020

BUY
$1.0 - $8.5 $13,000 - $110,500
13,000 New
13,000 $59,000

Others Institutions Holding CAPR

About CAPRICOR THERAPEUTICS, INC.


  • Ticker CAPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,346,200
  • Market Cap $450M
  • Description
  • Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...
More about CAPR
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.